Article
Author(s):
Delivery into the suprachoroidal space may potentially extend the duration of therapeutic action and reduce or relieve the treatment burden for wet AMD.
Zeiss Medical Technology gains NMPA approval for ILM-Blue in China
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
ZEISS VISULAS Combi availability expands to Canada
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Staying the course in shifting winds
US News & World Report releases list of best ophthalmology ambulatory surgical centers in the US